| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer H Hurwitz, L Fehrenbacher, W Novotny, T Cartwright, J Hainsworth, ... New England journal of medicine 350 (23), 2335-2342, 2004 | 13217 | 2004 |
| Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial A Rittmeyer, F Barlesi, D Waterkamp, K Park, F Ciardiello, J Von Pawel, ... The Lancet 389 (10066), 255-265, 2017 | 4619 | 2017 |
| First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer L Horn, AS Mansfield, A Szczęsna, L Havel, M Krzakowski, MJ Hochmair, ... New England Journal of Medicine 379 (23), 2220-2229, 2018 | 2723 | 2018 |
| Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non … DH Johnson, L Fehrenbacher, WF Novotny, RS Herbst, JJ Nemunaitis, ... Journal of Clinical Oncology 22 (11), 2184-2191, 2004 | 2480 | 2004 |
| Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer F Kabbinavar, HI Hurwitz, L Fehrenbacher, NJ Meropol, WF Novotny, ... Journal of clinical oncology 21 (1), 60-65, 2003 | 2303 | 2003 |
| Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial FF Kabbinavar, J Schulz, M McCleod, T Patel, JT Hamm, JR Hecht, ... Journal of Clinical Oncology 23 (16), 3697-3705, 2005 | 1245 | 2005 |
| Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab FA Scappaticci, JR Skillings, SN Holden, HP Gerber, K Miller, ... Journal of the National Cancer Institute 99 (16), 1232-1239, 2007 | 1119 | 2007 |
| Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer FF Kabbinavar, J Hambleton, RD Mass, HI Hurwitz, E Bergsland, S Sarkar Journal of clinical oncology 23 (16), 3706-3712, 2005 | 907 | 2005 |
| Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers M Pegram, S Hsu, G Lewis, R Pietras, M Beryt, M Sliwkowski, D Coombs, ... Oncogene 18 (13), 2241-2251, 1999 | 892 | 1999 |
| Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer HI Hurwitz, L Fehrenbacher, JD Hainsworth, W Heim, J Berlin, ... Journal of Clinical Oncology 23 (15), 3502-3508, 2005 | 798 | 2005 |
| Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab FA Scappaticci, L Fehrenbacher, T Cartwright, JD Hainsworth, W Heim, ... Journal of surgical oncology 91 (3), 173-180, 2005 | 633 | 2005 |
| Overexpression of AKT2/protein kinase Bβ leads to up-regulation of β1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells MJ Arboleda, JF Lyons, FF Kabbinavar, MR Bray, BE Snow, R Ayala, ... Cancer research 63 (1), 196-206, 2003 | 633 | 2003 |
| Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer MR Smith, F Kabbinavar, F Saad, A Hussain, MC Gittelman, DL Bilhartz, ... Journal of Clinical Oncology 23 (13), 2918-2925, 2005 | 591 | 2005 |
| Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial RS Herbst, Y Sun, WEE Eberhardt, P Germonpré, N Saijo, C Zhou, ... The lancet oncology 11 (7), 619-626, 2010 | 499 | 2010 |
| Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal … AM Jubb, HI Hurwitz, W Bai, EB Holmgren, P Tobin, AS Guerrero, ... Journal of clinical oncology 24 (2), 217-227, 2006 | 471 | 2006 |
| Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab WL Ince, AM Jubb, SN Holden, EB Holmgren, P Tobin, M Sridhar, ... Journal of the National Cancer Institute 97 (13), 981-989, 2005 | 399 | 2005 |
| Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer RM Bukowski, FF Kabbinavar, RA Figlin, K Flaherty, S Srinivas, ... Journal of clinical oncology 25 (29), 4536-4541, 2007 | 366 | 2007 |
| Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study M Kozloff, MU Yood, J Berlin, PJ Flynn, FF Kabbinavar, DM Purdie, ... The oncologist 14 (9), 862-870, 2009 | 365 | 2009 |
| Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials HI Hurwitz, NC Tebbutt, F Kabbinavar, BJ Giantonio, ZZ Guan, L Mitchell, ... The oncologist 18 (9), 1004-1012, 2013 | 294 | 2013 |
| Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium CJ Sweeney, BJ Roth, FF Kabbinavar, DJ Vaughn, M Arning, RE Curiel, ... Journal of Clinical Oncology 24 (21), 3451-3457, 2006 | 290 | 2006 |
